Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX EV / sales

EV / sales at other companies

Avanos Medical logo
Avanos MedicalAVNS
1×0.0×
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
1×-0.3×
AtriCure logo
AtriCureATRC
2.4×-0.8×

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

enterprise value/total revenue=1.6×

Based on the most recent quarter.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s EV / sales?
Pacira BioSciences, Inc. (PCRX) reported EV / sales of 1.6× in Q1 2026.
How has Pacira BioSciences, Inc.'s EV / sales changed year-over-year?
Pacira BioSciences, Inc.'s EV / sales decreased by 7.6% year-over-year, from 1.7× to 1.6×.
What is the long-term trend for Pacira BioSciences, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s EV / sales has grown at a -21.9% compound annual growth rate (CAGR), from 6.5× to 1.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.